This webinar will provide an up-to-date overview on accurate, clinically relevant classification of pituitary tumours with routine histological and advanced molecular techniques.


In the webinar, following the review of pituitary gland development, clinically relevant classification of posterior pituitary tumours and specific recommendations for classification of neuroendocrine tumours of adenohypophysis will be discussed. To compare the diagnostic approach to classification of pituitary tumours across the UK centres with recently proposed diagnostic criteria, findings from a national audit will be presented. The landscape of genetic alterations observed in pituitary tumours and their role in diagnostics and biological behaviour will be addressed. An approach for classification of neuroendocrine tumours of adenohypophysis integrating histological and molecular findings will be presented.

The webinar will be supplemented with interactive practical session, where participants will have the opportunity to discuss the diagnostic approach of pituitary tumours. These cases will be available for viewing in a digital format prior, during and after the webinar for registered participants.

Target audience

Consultants and trainees in neuropathology and general histopathology interested in diagnostics of pituitary tumours.



Friday 23 April 2021 

  • 09:30 Registration  
  • 09:35 Welcome, Dr Zane Jaunmuktane
  • 09:40 Pituitary development, Dr Carles Gaston-Massuet, London
  • 10:00 Posterior pituitary tumours, Professor Federico Roncaroli, Manchester
  • 10:20 PitNET 2017 classification, Associate Professor Olivera Casar-Borota, Sweden
  • 10:40 UK practice: audit, Jillian Davis & Elizabeth Byrne, trainee representatives, Nottingham & Oxford
  • 10:50 Discussion: Classification and audit outcome, all speakers
  • 11:00 Break
  • 11:25 Genetics of adenomas (PitNETs), Professor Marta Korbonits, London
  • 11:45 Molecular pathology of PitNETs – towards an integrated histomolecular diagnosis, Olaf Ansorge, Oxford
  • 12:05 Q&A
  • 12:10 Break  
  • 12:25 Case examples, with digital pathology available beforehand – Professor Federico Roncaroli, Olaf Ansorge, Professor Sebastian Brandner and Dr Zane Jaunmuktane
  • 13:25 Event Close


Registration Fees

Online rates
Members £82.50
Non-members £133.00
Concessional £44.00 - Includes trainees, BMS, non-consultant Clinical Scientists, retired & nurses

Please note that an administrative charge of £10.00 will be made on all cancellations and the total registration fee is forfeited if cancelled one working week before the event.



This meeting will be held via Zoom. Details of the meeting with accompanied guidance will be sent to attendees before the meeting. We strongly suggest you download Zoom to your computer/laptop to make the most of the meeting, however if this is not possible just simply click on the link provided. To Find out more about Zoom and how it works please visit the website

Please note: If you experience any problems when connecting to your Zoom meeting, such as lagging or freezing, then this may indicate that there is an issue with your internet connection, or the device you are using. We suggest that you try to move to an area with a more stable connection and then re-join the meeting. We unfortunately will not be able to provide you with a refund or transfer you onto another event if you happen to encounter these problems on the day. 




Pituitary Pathology

  • Dr Zane Jaunmuktane

    Dr Zane Jaunmuktane is a clinical lecturer and honorary consultant neuropathologist in the Division of Neuropathology, University College London, Queen Square Institute of Neurology and the Department of Clinical and Movement Neurosciences, Queen Square Brain Bank. One of her areas of expertise is in molecular diagnostics of adult brain tumours. She is particularly interested in implementing in routine clinical practice advanced molecular technologies for brain tumour classification, such as epigenetic profiling of neoplasms with methylation arrays.

  • Professor Sebastian Brandner

    I started my research career during Medical School in Göttingen, and in 1993 joined the Institute of Neuropathology in Zurich, where I started my research on prion disease. I discovered that prions are toxic to nerve cells only when these express the normal PrP isoform, resulting in highly cited publications in Nature and PNAS. During my postdoctoral training I also developed an interest in the pathogenesis of brain tumours and I established my own research group. In 2001, I was recruited through the MRC international recruitment scheme to join the MRC Prion Unit at UCL Institute of Neurology and in 2004 I was appointed as Chair of Neuropathology and Head of the Division of Neuropathology at Queen Square. 
    In the field of neurodegenerative research I conducted several studies, funded by Public Health England, to screen the prevalence for the presence of vCJD prions in the UK. Our findings have important implications for the management of blood and blood products and for the handling of surgical instruments. Recently we discovered that amyloid beta, one of the proteins aggregating in Alzheimer’s disease can be transmitted through medical procedures, published in Nature (2015) and Acta Neuropathologica (2018). 
    My research on brain tumours resulted in publications in Development, EMBO Journal (2010), Cancer Research (2013), Disease Models and Mechanisms (2016), and Oncogene (2018) showing how stem- and progenitor cells of the adult brain can give rise to brain tumours and how these tumours relate to human disease. 
    I am Training Programme Director in Diagnostic Neuropathology for London and co-opted member for the Specialty Advisory Committee and the Clinical Practice Committee of the British Neuropathology Society. I am Council member at the Royal College of pathologists.
    I am clinically active and lead the Diagnostic Molecular Pathology Service at the National Hospital. This service has over the last five years developed significantly, now serving several large catchment areas in the United Kingdom. Our most recent service development includes establishing methylation array analysis, available to pathologists and oncologists in the UK and overseas. We have recently published our experience with this technology In Acta Neuropathologica Communications (2019). 

  • Professor Márta Korbonits

    Márta Korbonits, Professor of Endocrinology and Metabolism, is a clinical academic at Barts. Her current interests include endocrine tumorigenesis, especially the genetic origin of pituitary adenomas and other endocrine tumour syndromes. She works on both the clinical characterisation as well as molecular aspects of pituitary diseases and leads a large international consortium to study these rare conditions. She published over 200 original papers and has a Google H-index of 73. She shares her time between clinical patient care, clinical research and laboratory based research as well as teaching at undergraduate and postgraduate level. She was a recipient of several national and international awards and was serving on the Executive Committee of ENEA, SfE and ESE. In 2019 she has been elected as a Member of the Hungarian Academy of Sciences. She is incoming Deputy Editor of Endocrine-Related Cancer.

  • Professor Federico Roncaroli

    Federico Roncaroli is professor of Clinical Neuropathology. He serves as director of the Manchester Brain Bank and Associate Clinical Director of Cellular Pathology at the Northern Care Alliance. 

    He graduated in medicine and completed his training in Histopathology at the University of Turin in Italy. Since 2015, he works at Geoffrey Jefferson Brain Research Centre at the University of Manchester.

    He authored and co-authored about 200 peer reviewed publications and book chapters including contributions to the WHO classifications of CNS Tumours and Pituitary Tumours. He co-founded the European Pituitary Pathology Group and is a member of the International Pituitary Pathology Club.

  • Dr Carles Gaston-Massuet

    Graduated in Biomedical Sciences from Barcelona University with an exchange programme at King’s College London. I obtained a PhD in Developmental Genetics from Institute of Child Health, UCL, under Professor Andrew Copp’s supervision, where I studied the genetics of congenital birth defects of the central nervous system. Postdoctoral training in Dr Martinez-Barbera’s Lab, UCL, to study congenital abnormalities of hypothalamo-pituitary (HP) axis development. In 2009, I was awarded a Research Fellowship from the NIHR to study the underlying molecular mechanisms of the endocrine paediatric tumours craniopharyngioma.

    Among my key findings are the identification of Wnt/b-catenin pathways as underlying aetiology of adamantinomas craniopharyngioma (Gaston-Massuet, PNAS 2011). Identification of components of the Wnt pathways in human hypopituitarism (Gaston-Massuet, PNAS 2016) & other key regulatory genes in HP-axis development both in murine models and humans, such as Fgf8 (Gaston-Massuet, JCEM 2011); Prokr2 (Gaston-Massuet, JCEM 2013); Foxa2 (Giri et al. HMG 2017), and most recently the involvement of mutations in MAPK-pathway previously associated to RASopathies in endocrine deficiencies in humans (Gualtieri, et al. Nat Communications 2021).

  • Olaf Ansorge

    Olaf Ansorge is a consultant neuropathologist at the Oxford University Hospitals NHS Foundation Trust and the Director of the Academic Unit of Neuropathology and Oxford Brain Bank in the Nuffield Department of Clinical Neurosciences at the University of Oxford. He has research interests in neurodegeneration and neurooncology, including pituitary neoplasms. He is a member of the European Pituitary Pathology Group.